Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
IBI3013 or baricitinib for nonsegmental vitiligo
Official title: Evaluation of the Safety, Tolerability, and Pharmacokinetics of Single-dose Administration of IBI3013 in Healthy Adult Trial Participants and Multiple-dose Administration in Active Non-segmental Vitiligo Trial Participants and Severe Alopecia Areata Trial Participants - a Randomized, Double-blind, Placebo-controlled, Dose-escalation Study
Status: Recruiting now
Description:
Innovent Biologics (Suzhou) Co. Ltd. plans to enroll about 160 participants. The experimental antibody blocks IL-15, an immune signal that helps pigment-destroying T cells survive. Researchers hope it will reduce the immune attack on melanocytes and allow skin color to return. Possible risks include injection or infusion reactions, headache, and infections; longer-term risks are still being studied. People ages 18 to 80 may qualify. The study is recruiting at one listed site in China.
Start date: April 18, 2026
Completion date: December 31, 2028
Organizer: Innovent Biologics (Suzhou) Co. Ltd.
Contact: juan chen
Tel.: 021 3183 7200
Email: juan.chen01@innoventbio.com
Clinical Trial Alerts
Sign up and be the first to know about updates on this trial.
FAQOther Questions
- Can chemicals cause vitiligo?
Certain chemicals can trigger vitiligo, leading to a condition known as chemical-induced vitiligo. While clinically and histologically indistinguishable from other types of viti...
- How can I explain vitiligo to my children?
Vitiligo can be confusing for children because it doesn’t resemble an "illness" in the typical sense. Choosing the right way to explain it depends on your child’s age and maturi...
- What's better: laser or phototherapy?
Laser therapy is actually a type of phototherapy. Both rely on light to trigger changes in the skin, but they work differently. Phototherapy usually means a narrow-band UV (NB-U...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.